NCT00690560 2025-09-30
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Centre Antoine Lacassagne
Phase 2 Completed
Clinical Trials
47 trialsNCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
NCT00168727 2023-08-23
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Biogen
Phase 4 Completed
NCT00493467 2022-09-15
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02063685 2022-06-21
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT00290511 2022-04-22
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01448928 2021-10-01
ZEVALIN-DUI
Spectrum Pharmaceuticals, Inc
Completed
NCT00562978 2021-06-18
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
City of Hope Medical Center
Phase 1/2 Completed
NCT00591630 2021-02-02
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00058422 2020-11-12
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00491491 2020-08-31
Zevalin-beam for Aggressive Lymphoma
Sheba Medical Center
Phase 3 Completed
NCT01490723 2020-05-05
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00662948 2020-04-28
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
PETHEMA Foundation
Phase 2 Completed
NCT01493479 2019-10-15
FIZZ
The Christie NHS Foundation Trust
Phase 2 Completed
NCT00732498 2019-09-04
ESHAP
University of Arizona
Phase 2 Completed
NCT00392691 2019-05-15
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Swiss Cancer Institute
Phase 1 Completed
NCT01686165 2018-08-28
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
University of Arizona
Phase 2 Completed
NCT00695409 2018-07-06
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT00119392 2018-06-29
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00477815 2018-05-14
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT00073957 2018-01-23
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00644371 2017-03-27
Z-RIC-Allo
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00334438 2016-12-23
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00607854 2016-10-05
ZEVALLO
University Hospital, Bordeaux
Phase 2 Completed
NCT00062114 2016-07-06
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01446562 2016-06-17
ZEVISS
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT00646750 2016-02-15
Z-BEAM LDGGB
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00453102 2016-01-01
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
University of Miami
Phase 2 Completed
NCT01130194 2014-05-12
MasterPlan
St. Louis University
Phase 2 Completed
NCT00119730 2014-04-24
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00387023 2013-11-18
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
M.D. Anderson Cancer Center
Phase NA Completed
NCT00521560 2013-02-15
escZ-BEAM
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Phase 2 Completed
NCT00064246 2013-01-25
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00082836 2013-01-17
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00017381 2013-01-09
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Completed
NCT00186589 2012-06-06
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
Stanford University
Phase 1 Completed
NCT00058292 2012-06-01
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Northwestern University
Phase 1 Completed
NCT00514475 2012-05-04
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma
Oslo University Hospital
Phase 2 Completed
NCT00505232 2012-01-02
LCM-04-02
CABYC
Phase 2 Completed
NCT01479387 2011-11-24
ZEVALIN-SDUI
Bayer
Completed
NCT00038623 2011-11-02
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00193440 2010-12-30
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01164696 2010-08-24
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
Bayer
Completed
NCT01157988 2010-07-08
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma
Chonnam National University Hospital
Phase 2 Completed
NCT00859001 2009-03-12
FM+R-Z
University of Bologna
Phase 2 Completed
NCT00138086 2006-09-08
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
Lymphoma Study Association
Phase 2 Completed